RESUMEN
OBJECTIVE: The coronavirus disease 2019 pandemic has greatly disrupted head and neck cancer services in the West of Scotland. This study aimed to assess the impact of the first wave of the pandemic on cancer waiting times. METHODS: A retrospective review of multidisciplinary team records was undertaken between March and May in 2019 and the same months in 2020. Time-to-diagnosis and time-to-treatment for new cancers treated with curative intent were compared between the study periods, and subclassified by referral pathway. RESULTS: A total of 236 new cancer patients were included. During the pandemic, pathways benefitted from reduced diagnostic and treatment times resulting from the restructuring of service provisions. A 75 per cent reduction in secondary care referrals and a 33 per cent increase in urgent suspicion of cancer referrals were observed in 2020. CONCLUSION: Head and neck cancer pathway times did not suffer because of the coronavirus pandemic. Innovations introduced to mitigate issues brought about by coronavirus benefitted patients, led to a more streamlined service, and improved diagnostic and treatment target compliance.
Asunto(s)
COVID-19 , Neoplasias de Cabeza y Cuello , COVID-19/epidemiología , Neoplasias de Cabeza y Cuello/diagnóstico , Neoplasias de Cabeza y Cuello/epidemiología , Neoplasias de Cabeza y Cuello/terapia , Humanos , Pandemias , Derivación y Consulta , Escocia/epidemiologíaRESUMEN
Previous studies have suggested that a high intake of sugar-sweetened beverages is positively associated with the risk of a coronary event. However, a few studies have examined the association between sucrose (the most common extrinsic sugar in Sweden) and incident coronary events. The objective of the present study was to examine the associations between sucrose intake and coronary event risk and to determine whether these associations are specific to certain subgroups of the population (i.e. according to physical activity, obesity status, educational level, alcohol consumption, smoking habits, intake of fat and intake of fruits and vegetables). We performed a prospective analysis on 26 190 individuals (62 % women) free from diabetes and without a history of CVD from the Swedish population-based Malmö Diet and Cancer cohort. Over an average of 17 years of follow-up (457 131 person-years), 2493 incident cases of coronary events were identified. Sucrose intake was obtained from an interview-based diet history method, including 7-d records of prepared meals and cold beverages and a 168-item diet questionnaire covering other foods. Participants who consumed >15 % of their energy intake (E%) from sucrose showed a 37 (95 % CI 13, 66) % increased risk of a coronary event compared with the lowest sucrose consumers (<5 E%) after adjusting for potential confounders. The association was not modified by the selected lifestyle factors. The results indicated that sucrose consumption higher than 15 E% (5 % of this population) is associated with an increased risk of a coronary event.
Asunto(s)
Dieta/efectos adversos , Sacarosa en la Dieta/efectos adversos , Estilo de Vida , Isquemia Miocárdica/etiología , Salud Urbana , Adulto , Anciano , Estudios de Cohortes , Factores de Confusión Epidemiológicos , Dieta/etnología , Sacarosa en la Dieta/administración & dosificación , Ingestión de Energía/etnología , Conducta Alimentaria/etnología , Femenino , Estudios de Seguimiento , Estilo de Vida Saludable , Humanos , Incidencia , Estilo de Vida/etnología , Masculino , Persona de Mediana Edad , Isquemia Miocárdica/epidemiología , Isquemia Miocárdica/etnología , Isquemia Miocárdica/prevención & control , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Sistema de Registros , Factores de Riesgo , Autoinforme , Suecia/epidemiología , Salud Urbana/etnologíaRESUMEN
OBJECTIVE: To characterize meal patterns across ten European countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study. DESIGN: Cross-sectional study utilizing dietary data collected through a standardized 24 h diet recall during 1995-2000. Eleven predefined intake occasions across a 24 h period were assessed during the interview. In the present descriptive report, meal patterns were analysed in terms of daily number of intake occasions, the proportion reporting each intake occasion and the energy contributions from each intake occasion. SETTING: Twenty-seven centres across ten European countries. SUBJECTS: Women (64 %) and men (36 %) aged 35-74 years (n 36 020). RESULTS: Pronounced differences in meal patterns emerged both across centres within the same country and across different countries, with a trend for fewer intake occasions per day in Mediterranean countries compared with central and northern Europe. Differences were also found for daily energy intake provided by lunch, with 38-43 % for women and 41-45 % for men within Mediterranean countries compared with 16-27 % for women and 20-26 % for men in central and northern European countries. Likewise, a south-north gradient was found for daily energy intake from snacks, with 13-20 % (women) and 10-17 % (men) in Mediterranean countries compared with 24-34 % (women) and 23-35 % (men) in central/northern Europe. CONCLUSIONS: We found distinct differences in meal patterns with marked diversity for intake frequency and lunch and snack consumption between Mediterranean and central/northern European countries. Monitoring of meal patterns across various cultures and populations could provide critical context to the research efforts to characterize relationships between dietary intake and health.
Asunto(s)
Encuestas sobre Dietas , Dieta , Conducta Alimentaria , Adulto , Anciano , Estudios Transversales , Ingestión de Energía , Europa (Continente) , Femenino , Humanos , Masculino , Comidas , Persona de Mediana Edad , Estudios Prospectivos , BocadillosRESUMEN
NTRODUCCIÓN El tabaquismo es la principal causa global prevenible de morbi-mortalidad. Produjo alrededor de 6 millones de muertes en 2014, además de enfermedades y discapacidades asociadas. Existen diferentes estrategias para reducir su consumo, entre ellas los tratamientos farmacológicos. Argentina cuenta con información actualizada sobre las consecuencias económicas derivadas de su consumo pero la información referida a los costos de las diferentes alternativas de tratamiento es más limitada. OBJETIVOS Identificar los tratamientos farmacológicos más costo-efectivos para reducir la adicción al tabaco. MÉTODOS Se realizó un estudio cuantitativo descriptivo, que utilizó como eje el modelo de los análisis de costo-efectividad (ACE). Se calcularon los costos de los tratamientos recomendados en la Guía de Práctica Clínica Nacional de Tratamiento de la Adicción al Tabaco del Ministerio de Salud de la Nación (2011) para la población de 15 años o más, sin cobertura explícita de salud, fumadora y con un intento por dejar de fumar en los últimos 12 meses mediante algún método farmacológico. Se construyeron indicadores de calidad de vida (años de vida saludable, AVISA) y se estimaron los costos necesarios para la atención médica de patologías asociadas al tabaquismo. RESULTADOS Si se contemplan los tres tipos de tratamientos recomendados por la Guía, sería necesario invertir alrededor de $29,5 millones de pesos (a precios de mediados de 2013). El tratamiento farmacológico más costo-efectivo es el bupropión, seguido por la terapia de reemplazo nicotínico (TRN) y la vareniclina. DISCUSIÓN Invirtiendo en la cesación tabáquica se generaría un ahorro de 52 313 AVISA y de $779,5 millones en los costos de atención médica de las patologías seleccionadas. Para obtener un solo AVISA es necesario invertir $564 en el financiamiento de los tratamientos farmacológicos. Por cada peso invertido en tratamientos farmacológicos se ahorran $26,4 en todo lo referido a la atención médica.
Asunto(s)
Cese del Uso de Tabaco , Análisis de Costo-EfectividadRESUMEN
BACKGROUND/OBJECTIVES: Phytoestrogens are estradiol-like natural compounds found in plants that have been associated with protective effects against chronic diseases, including some cancers, cardiovascular diseases and osteoporosis. The purpose of this study was to estimate the dietary intake of phytoestrogens, identify their food sources and their association with lifestyle factors in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. SUBJECTS/METHODS: Single 24-hour dietary recalls were collected from 36,037 individuals from 10 European countries, aged 35-74 years using a standardized computerized interview programe (EPIC-Soft). An ad hoc food composition database on phytoestrogens (isoflavones, lignans, coumestans, enterolignans and equol) was compiled using data from available databases, in order to obtain and describe phytoestrogen intakes and their food sources across 27 redefined EPIC centres. RESULTS: Mean total phytoestrogen intake was the highest in the UK health-conscious group (24.9 mg/day in men and 21.1 mg/day in women) whereas lowest in Greece (1.3 mg/day) in men and Spain-Granada (1.0 mg/day) in women. Northern European countries had higher intakes than southern countries. The main phytoestrogen contributors were isoflavones in both UK centres and lignans in the other EPIC cohorts. Age, body mass index, educational level, smoking status and physical activity were related to increased intakes of lignans, enterolignans and equol, but not to total phytoestrogen, isoflavone or coumestan intakes. In the UK cohorts, the major food sources of phytoestrogens were soy products. In the other EPIC cohorts the dietary sources were more distributed, among fruits, vegetables, soy products, cereal products, non-alcoholic and alcoholic beverages. CONCLUSIONS: There was a high variability in the dietary intake of total and phytoestrogen subclasses and their food sources across European regions.
Asunto(s)
Dieta , Ingestión de Energía , Neoplasias/prevención & control , Estado Nutricional , Fitoestrógenos/administración & dosificación , Adulto , Anciano , Bebidas , Índice de Masa Corporal , Enfermedades Cardiovasculares/prevención & control , Cumarinas/administración & dosificación , Grano Comestible , Equol/administración & dosificación , Europa (Continente) , Femenino , Frutas , Humanos , Isoflavonas/administración & dosificación , Estilo de Vida , Lignanos/administración & dosificación , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Glycine max , VerdurasRESUMEN
OBJECTIVES: To examine the associations between food patterns constructed using cluster analysis and markers of systemic and vascular inflammation, and incident cardiovascular disease (CVD) after 13 years of follow-up. DESIGN: Population-based, prospective cohort study. SETTING AND SUBJECTS: Cluster analysis identified six food patterns from 43 food group variables among 4999 subjects, aged 45-68 years, who participated in the Malmö Diet and Cancer cardiovascular programme between 1991 and 1994. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2) ), C-reactive protein concentration and white blood cell (WBC) count were measured using blood samples at baseline. Incidence of CVD (coronary events and ischaemic stroke) was monitored over 13 years of follow-up. RESULTS: The fibre-rich bread pattern was associated with favourable effects on WBC count in women, and the low-fat and high-fibre pattern with favourable effects on Lp-PLA(2) mass in women, and on Lp-PLA(2) activity in men. However, the milk fat and sweets and cakes patterns were both associated with adverse effects; the former on WBC count in women and on Lp-PLA(2) mass in men, and the latter on WBC count and Lp-PLA(2) mass in women. The milk fat and sweets and cakes patterns were associated with increased CVD risk in women. CONCLUSIONS: The results of this study support the present Nordic dietary recommendations indicating that diets rich in high-fibre, low-fat and low-sugar foods are favourably associated with markers of inflammation and, potentially, with CVD risk.
Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Dieta , Lipoproteínas/sangre , Neoplasias/epidemiología , Anciano , Biomarcadores/sangre , Enfermedades Cardiovasculares/sangre , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Humanos , Inflamación/sangre , Inflamación/epidemiología , Modelos Lineales , Linfocitos , Masculino , Persona de Mediana Edad , Neoplasias/sangre , Estudios Prospectivos , Factores de Riesgo , Factores Socioeconómicos , Encuestas y Cuestionarios , Suecia/epidemiologíaRESUMEN
BACKGROUND: Helicobacter pylori infection leads to an increased risk of developing gastric cancer. The mechanism through which this occurs is not known. We aimed to determine the effect of H. pylori and gastritis on levels of DNA damage in gastric epithelial cells. METHODS: Epithelial cells were isolated from antral biopsies from 111 patients. DNA damage was determined using single cell gel electrophoresis and the proportion of cells with damage calculated before and 6 weeks after eradication of H. pylori. Cell suspensions generated by sequential digestions of the same biopsies were assayed to determine the effect of cell position within the gastric pit on DNA damage. RESULTS: DNA damage was significantly higher in normal gastric mucosa than in H. pylori gastritis [median (interquartile range) 65% (58.5-75.8), n = 18 and 21% (11.9-29.8), n = 65, respectively, p <.001]. Intermediate levels were found in reactive gastritis [55.5% (41.3-71.7), n = 13] and H. pylori negative chronic gastritis [50.5% (36.3-60.0), n = 15]. DNA damage rose 6 weeks after successful eradication of H. pylori[to 39.5% (26.3-51.0), p =.007] but was still lower than in normal mucosa. Chronic inflammation was the most important histological factor that determined DNA damage. DNA damage fell with increasing digestion times (r = -.92 and -.88 for normal mucosa and H. pylori gastritis, respectively). CONCLUSIONS: Lower levels of DNA damage in cells isolated from H. pylori infected gastric biopsies may be a reflection of increased cell turnover in H. pylori gastritis. The investigation of mature gastric epithelial cells for DNA damage is unlikely to elucidate the mechanisms underlying gastric carcinogenesis.
Asunto(s)
Daño del ADN , Células Epiteliales/patología , Mucosa Gástrica/patología , Gastritis/patología , Infecciones por Helicobacter/patología , Helicobacter pylori , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Ensayo Cometa , Células Epiteliales/microbiología , Femenino , Mucosa Gástrica/microbiología , Gastritis/microbiología , Infecciones por Helicobacter/microbiología , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Helicobacter pylori is an independent risk factor for gastric cancer, and this association may be due to the bacterium causing reactive oxygen species mediated damage to DNA in the gastric epithelium. High dietary ascorbic acid intake may protect against gastric cancer by scavenging reactive oxygen species. AIMS: To assess reactive oxygen species activity and damage in gastric mucosa in relation to gastric pathology and mucosal ascorbic acid level, and to determine the effect of H pylori eradication on these parameters. PATIENTS: Gastric biopsy specimens were obtained for analysis from 161 patients undergoing endoscopy for dyspepsia. METHODS: Reactive oxygen species activity and damage was assessed by luminol enhanced chemiluminescence and malondialdehyde equivalent estimation respectively. Ascorbic acid concentrations were measured using HPLC. RESULTS: Chemiluminescence and malondialdehyde levels in gastric mucosa were higher in patients with H pylori gastritis than in those with normal histology. Successful eradication of the bacterium led to decreases in both parameters four weeks after treatment was completed. Gastric mucosal ascorbic acid and total vitamin C concentrations were not related to mucosal histology, but correlated weakly with reactive oxygen species activity (chemiluminescence and malodialdehyde levels). CONCLUSIONS: Data suggest that reactive oxygen species play a pathological role in H pylori gastritis, but mucosal ascorbic acid is not depleted in this condition.
Asunto(s)
Gastritis/metabolismo , Infecciones por Helicobacter/metabolismo , Helicobacter pylori , Peroxidación de Lípido , Especies Reactivas de Oxígeno/metabolismo , Adulto , Anciano , Ácido Ascórbico/análisis , Ácido Ascórbico/metabolismo , Cromatografía Líquida de Alta Presión , Femenino , Mucosa Gástrica/química , Mucosa Gástrica/metabolismo , Gastritis/tratamiento farmacológico , Gastritis/microbiología , Infecciones por Helicobacter/tratamiento farmacológico , Humanos , Mediciones Luminiscentes , Masculino , Malondialdehído/análisis , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
The carotenoids--lycopene and alpha- and beta-carotene-- and alpha-tocopherol were measured in plasma and in mucosal biopsies in normal subjects and in those infected with Helicobacter pylori. Two indexes of the presence of the reactive oxygen species malondialdehyde and chemiluminescence were measured in biopsies taken from adjacent sites in the same patient. In general, plasma and mucosal concentrations of all antioxidants correlated well and were of a similar order or magnitude in plasma and mucosa. There was no significant difference between the slope of the regression lines nor an overall difference in the concentrations of these antioxidants between the H. pylori-positive and control groups, indicating an absence of effect of H. pylori infection. However, a marked difference was seen in chemiluminescence and malondialdehyde concentrations in biopsies. For chemiluminescence this was highly significant. These findings confirm the presence of free radicals in the mucosa of H. pylori-infected patients and suggest therefore that the lipid-soluble antioxidants have either no role in protecting mucosal cells from free radical damage or, if they are able to scavenge these species, they are then rapidly regenerated to their original forms by redox and other processes.
Asunto(s)
Carotenoides/análisis , Mucosa Gástrica/química , Gastritis/sangre , Infecciones por Helicobacter/sangre , Helicobacter pylori , Vitamina E/análisis , Adulto , Biopsia , Carotenoides/sangre , Carotenoides/metabolismo , Cromatografía Líquida de Alta Presión , Femenino , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patología , Gastritis/etiología , Gastritis/metabolismo , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/metabolismo , Humanos , Modelos Lineales , Mediciones Luminiscentes , Masculino , Malondialdehído/análisis , Persona de Mediana Edad , Oxidación-Reducción , Especies Reactivas de Oxígeno , Vitamina E/sangre , Vitamina E/metabolismoRESUMEN
OBJECTIVE: To compare the efficacy and safety of ranitidine 300 mg twice daily plus amoxycillin 1000 mg twice daily for 2 weeks (RA2) with ranitidine 300 mg twice daily, amoxycillin 1000 mg twice daily, plus tinidazole 500 mg twice daily for 2 weeks (RAT2) for the eradication of Helicobacter pylori. DESIGN: Prospective, randomized, double-blind, parallel-group study in patients who were H. pylori positive on 13C urea breath test (13C UBT). SETTING: Twenty-four UK consultant gastroenterologists entered mostly hospital out-patients. PATIENTS: A total of 232 patients with gastric or duodenal ulceration or endoscopic appearances suggestive of gastritis (160 male, 72 female, mean age 51) were entered following routine endoscopy; 223 were H. pylori positive on 13C UBT. Patients with medical conditions or medications which could interfere with study response or measurements and those at risk of pregnancy were excluded. Two hundred and three patients completed the study. INTERVENTIONS: Patients underwent endoscopy with biopsy for rapid urease (CLO) test. Those who were positive had a 13C UBT. Patients were randomized to receive RA2 or RAT2. Eradication of H. pylori was assessed by 13C UBT 4 weeks after completion of therapy. Blood was taken for haematological and biochemical screening at the beginning and end of treatment. MAIN OUTCOME MEASURE: H. pylori eradication at least 28 days after end of treatment. RESULTS: In the intention-to-treat sample analysis, H. pylori was eradicated in 78/115 patients (68%) taking RAT2 and 42/108 patients (39%) taking RA2. In the per-protocol sample analysis H. pylori eradication was successful in 68/79 patients (86%) taking RAT2 and 36/71 patients (51%) taking RA2. One hundred and seventeen patients experienced 242 adverse events. CONCLUSION: Twice daily ranitidine triple therapy is a useful H. pylori eradication regimen.
Asunto(s)
Antiulcerosos/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Ranitidina/uso terapéutico , Amoxicilina/administración & dosificación , Amoxicilina/uso terapéutico , Antiulcerosos/administración & dosificación , Método Doble Ciego , Esquema de Medicación , Quimioterapia Combinada , Femenino , Gastritis/tratamiento farmacológico , Gastritis/microbiología , Humanos , Masculino , Persona de Mediana Edad , Penicilinas/administración & dosificación , Penicilinas/uso terapéutico , Úlcera Péptica/tratamiento farmacológico , Úlcera Péptica/microbiología , Estudios Prospectivos , Ranitidina/administración & dosificación , Tinidazol/administración & dosificación , Tinidazol/uso terapéuticoRESUMEN
High dietary ascorbic acid intake appears to protect against gastric cancer. This may be due to its action as a scavenger of reactive radical species formed in the gastric mucosa, resulting in a reduced level of radical-mediated DNA damage. We have studied 82 patients, of whom 37 had Helicobacter pylori-associated gastritis, a condition which predisposes to gastric cancer. Using electron paramagnetic resonance (EPR) spectroscopy we have demonstrated, for the first time, that ascorbyl radicals are generated in human gastric mucosa, presumably as a result of scavenging of free radicals by ascorbic acid. Quantification of ascorbyl radicals demonstrates that there is a higher concentration in those patients with H.pylori gastritis compared with subjects with normal histology (P < 0.01). We also found gastric mucosal luminol-enhanced chemiluminescence and malondialdehyde concentrations (which are believed to be markers of radical generation and tissue damage) to be higher in patients with H.pylori gastritis compared with those with normal histology (P < 0.001 and P < 0.01 respectively). The observed concentrations of the ascorbyl radical correlate with the level of luminol-enhanced chemiluminescence (r = 0.41, P < 0.001), but not with malondialdehyde concentrations (r = 0.08, P = 0.47). Mucosal ascorbic acid and total vitamin C concentrations did not vary between histological groups, nor did they correlate with mucosal levels of the ascorbyl radical, chemiluminescence or malondialdehyde. These data suggest that ascorbic acid is acting as a scavenger of free radicals generated in human gastric mucosa. The experiments therefore provide direct supportive evidence for the hypothesis that ascorbic acid protects against gastric cancer by scavenging reactive radical species which would otherwise react with DNA, with resultant genetic damage.
Asunto(s)
Ácido Ascórbico/metabolismo , Depuradores de Radicales Libres/metabolismo , Mucosa Gástrica/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Neoplasias Gástricas/prevención & control , Adulto , Ácido Ascórbico/análisis , Mucosa Gástrica/química , Gastritis/microbiología , Infecciones por Helicobacter/metabolismo , Helicobacter pylori , Humanos , Mediciones Luminiscentes , Malondialdehído/análisis , Persona de Mediana EdadRESUMEN
Epidemiological evidence suggests that high dietary ascorbic acid reduces gastric cancer risk. It may do this by either reducing N-nitroso compound formation in gastric juice, or by scavenging reactive oxygen species in gastric mucosa. The aim of this study was to discover if potential ascorbic acid protection might be increased by supplementation. Thirty two patients were supplemented with ascorbic acid, 500 mg twice daily for two weeks. Gastric juice, plasma, and upper gastrointestinal biopsy ascorbate concentrations were measured and compared with values in 48 unsupplemented patients. It was found that ascorbic acid and total vitamin C concentrations were considerably higher in biopsy specimens from oesophagus, body, antrum, duodenum, and rectum, compared with values in plasma or gastric juice. Plasma and mucosal concentrations were unaffected by the presence of chronic gastritis but gastric juice concentrations were substantially lower in patients with chronic gastritis than in patients with normal histological assessment (p < 0.01). Patients receiving ascorbic acid supplements had higher ascorbic acid concentrations in plasma (p < 0.001), gastric juice (p < 0.001), and at all biopsy sites in the upper gastrointestinal tract (p < 0.05). Gastric juice ascorbic acid and total vitamin C concentrations in gastritic patients, however, were still less after supplementation than in normal subjects (p < 0.01). These data suggest that high ascorbic acid intake could reduce gastric cancer risk, but its protective effect might be greater if gastritis is treated (for example, by Helicobacter pylori eradication).
Asunto(s)
Ácido Ascórbico/metabolismo , Jugo Gástrico/metabolismo , Gastritis/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Ácido Ascórbico/administración & dosificación , Endoscopía Gastrointestinal , Esófago/metabolismo , Femenino , Mucosa Gástrica/metabolismo , Gastritis/tratamiento farmacológico , Humanos , Concentración de Iones de Hidrógeno , Mucosa Intestinal/metabolismo , Masculino , Persona de Mediana Edad , Antro Pilórico/metabolismo , Recto/metabolismoRESUMEN
1. Adenosine is well known to cause bronchoconstriction when inhaled, but to date, there has been only one report following the intravenous route. 2. Adenosine caused bronchoconstriction in two patients (the only two with asthma) out of 26 treated with the drug. In one subject the duration of response was much longer than previously reported following inhalation. 3. We suggest that adenosine may aggravate bronchospasm in some asthmatics and alternative treatments for supraventricular tachycardia should be considered in this group.